Upadacitinib APIs by Loncom Pharma represent a new generation of Janus kinase inhibitors, providing relief for autoimmune conditions such as rheumatoid arthritis. These APIs offer a new hope for patients with moderate to severe cases, where other treatments may not have been effective.
Shandong Loncom Pharmaceutical Co., Ltd is founded in 2012, located in Qihe Economic Development Zone, Shandong Province, with a registered capital of 60 million yuan.